New York, June 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hyperphosphatemia Treatment Global Market Report 2022" - https://www ...

Limited ('Alebund' or the 'Company'), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, today ...

Please provide your email address to receive an email when new articles are posted on . Low-dose sevelamer in combination with a calcium-based phosphorus binder may be used in resource-constrained ...

DUBAI, United Arab Emirates, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Future Market Insights estimates that the Hyperphosphatemia Market will experience a rapid expansion between the years 2023 and 2033. By ...

Please provide your email address to receive an email when new articles are posted on . Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on hyperphosphatemia. The report includes a comprehensive research on the pipeline molecules under ...

Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...

Nov. 4, 2002 — Lanthanum carbonate (Fosrenol) is safe and effective for the treatment of hemodialysis patients with hyperphosphatemia, according to two presentations on Nov. 2 at the American Society ...

As a physician and researcher caring for people with chronic kidney disease, I see firsthand the challenges that patients undergoing dialysis face. Dialysis is life-sustaining, but it also brings ...

WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Due to the lack of an appropriate dosage strength, Velphoro is not approved in pediatric patients 6 years to less than 9 years of age. The Food and Drug Administration (FDA) has expanded the approval ...

Diabetes, COPD Raise Post-Kidney Transplant Readmission Rates High phosphate levels are associated with 3.3-fold increased odds of 28-day in-hospital mortality. Hyperphosphatemia predicts an increased ...